What did @fissionfusiontraining actually say?
The creator laid out two categories of low libido causes, physiological and psychological, and then recommended PT-141 (bremelanotide) as a "quick fix you can use this weekend." They described it as working on "malano-court receptors" associated with the dopaminergic system. To their credit, they wrapped up by saying PT-141 is a temporary measure and that fixing underlying hormonal and psychological issues is the only real solution. That framing matters, but recommending a prescription peptide as a weekend hack to a TikTok audience of nearly 30,000 people is still a serious problem, regardless of the disclaimer tacked on at the end.
The creator also rattled off a list of hormonal culprits including hyperprolactinemia, low testosterone, high cortisol, and high estrogen. That list is not wrong in principle, but the casual delivery skips the clinical nuance those conditions actually require.
Does the science back this up?
The basic hormonal framework is grounded in real endocrinology, and PT-141's mechanism is mostly described correctly, though the receptor name was garbled. The evidence for bremelanotide in women with hypoactive sexual desire disorder (HSDD) is legitimate, supported by two Phase 3 randomized controlled trials. In men, the picture is thinner.
Bremelanotide works primarily on melanocortin receptors, specifically MC3R and MC4R, not purely through dopamine. It was FDA-approved in 2019 under the brand name Vyleesi for premenopausal women with HSDD. The pivotal trials (Kingsberg et al., 2019, Obstetrics and Gynecology) showed statistically significant improvements in desire and reductions in distress, though the effect sizes were modest. A mean increase of about 0.5 on a desire scale and a reduction of roughly 0.3 in distress scores does not exactly scream "huge boost." The creator's phrase "huge boost in sexual drive" oversells what the data actually shows, at least in the studied population.
For men, there is no FDA-approved indication. Small studies and clinical case reports exist, but nothing close to the evidence base supporting its use in women.
What did they get wrong (or right)?
They got the receptor name wrong. "Malano-court receptors" appears to be a mangled version of melanocortin receptors. That is not a minor slip because the mechanism is actually what distinguishes bremelanotide from PDE5 inhibitors like sildenafil. Getting it wrong suggests a surface-level understanding being presented with clinical confidence.
They also said PT-141 works on receptors "associated with the dopaminergic system." That is partially true but reductive. Melanocortin signaling interacts with dopaminergic pathways in the hypothalamus, but framing it as primarily a dopamine mechanism is misleading. It is not the same as a dopamine agonist.
What they got right: the two-bucket framework of physiological versus psychological causes is clinically sound. Low testosterone, hyperprolactinemia, high cortisol, and elevated estrogen are all legitimate drivers of reduced libido and are routinely assessed in clinical practice. They also correctly flagged that PT-141 does not fix the root cause. That responsible caveat should have been the headline, not the footnote.
What should you actually know?
PT-141 is a prescription drug in the United States. It is not a supplement you pick up and try "this weekend." Vyleesi is approved only for premenopausal women with HSDD and is administered by subcutaneous injection. Common side effects include nausea in roughly 40 percent of users, flushing, and transient increases in blood pressure, which is a meaningful concern for anyone with cardiovascular risk factors (Simon et al., 2019, Journal of Sexual Medicine).
Compounded versions of bremelanotide circulate widely through wellness clinics and peptide vendors, but compounded drugs are not FDA-approved and have no guarantee of purity, potency, or sterility. They are not equivalent to Vyleesi.
If you are experiencing low libido, the actual clinical path starts with bloodwork: total and free testosterone, prolactin, estradiol, TSH, and cortisol at minimum. That workup tells you whether you are dealing with something physiological before you consider any intervention. Telehealth platforms can run that panel and interpret the results in clinical context. Self-prescribing a peptide based on a TikTok video, even a mostly well-intentioned one, skips the step that determines whether the intervention is appropriate or safe for you.